Skip to content

DHR · DANAHER CORP /DE/

35 filings

10-K

DHR 10-K Annual Reports

DANAHER CORP /DE/ - 35 annual reports

Filing record · 2016–202610-K1110-Q328-K138

2025
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2025
Danaher Corporation (DHR) reported solid performance for the fiscal year ending December 31, 2025, with total sales increasing by 3.0% to $24.57 billion. The company's core sales, excluding currency impacts and acquisitions, grew by 2.0%, primarily driven by strength in the Biotechnology and Diagnostics segments, though the Life Sciences segment saw a slight decline. Net earnings from continuing operations were $3.60 billion, or $5.03 per diluted share, a decrease from the prior year primarily due to intangible asset impairments. Despite these impairments, Danaher maintained robust operating profit margins of 19.1%. The company's strategic focus on strengthening competitive advantages through the Danaher Business System (DBS), enhancing its portfolio via strategic capital allocation, and attracting top talent continues to guide its operations. Danaher also announced a significant pending acquisition of Masimo Corporation for approximately $9.9 billion, further underscoring its commitment to strategic growth in attractive science and technology markets.
Feb 24, 2026
2024
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2024
Danaher Corporation (DHR) reported flat total sales for the fiscal year ended December 30, 2024, with a 1.5% decrease in core sales. This performance was influenced by a 2.0% boost from acquisitions, which partially offset declines in the Biotechnology and Life Sciences segments, while the Diagnostics segment showed growth. Net earnings from continuing operations declined to $3.9 billion from $4.2 billion in the prior year, impacted by intangible asset impairments and increased operating expenses. The company's strategic priorities remain focused on strengthening competitive advantage through the Danaher Business System (DBS), enhancing its portfolio via strategic capital allocation, and attracting top talent. Looking ahead, Danaher has initiated a cost savings program expected to generate at least $150 million in annual pre-tax savings starting in Q1 2025. The company also continues to manage its capital structure, evidenced by significant share repurchases totaling $6.0 billion in 2024. Despite a challenging macro-economic environment, including global economic uncertainty and inflationary pressures, Danaher's diversified business model across life sciences, diagnostics, and biotechnology sectors provides a degree of resilience.
Feb 20, 2025
2023
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2023
Danaher Corporation (DHR) reported a decrease in total sales and net earnings for the fiscal year ended December 31, 2023, compared to the previous year. This decline was primarily driven by a significant reduction in demand for COVID-19 related products and a general slowdown in certain end markets. The company's core sales also saw a notable decrease. Despite the overall revenue decline, Danaher continued to execute its strategic priorities, including the significant acquisition of Abcam plc for $5.6 billion, strengthening its Life Sciences segment. The company also completed the separation of its former Environmental & Applied Solutions business into Veralto Corporation. Danaher's diversified business segments—Biotechnology, Life Sciences, and Diagnostics—face varying market dynamics, with Biotechnology experiencing the most pronounced sales decrease due to the normalization of COVID-19 related demand. The company remains focused on innovation, operational efficiency through its Danaher Business System (DBS), and strategic capital allocation for long-term shareholder value creation.
Feb 21, 2024
2022
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2022
Danaher Corporation reported solid performance for the fiscal year ending December 31, 2022, demonstrating resilience amidst economic uncertainties and supply chain challenges. The company achieved total sales growth of 7.0%, driven by a 9.5% increase in core sales, indicating strong underlying business performance. Net earnings from continuing operations rose to $7.2 billion, up from $6.3 billion in the prior year. The company's diverse segment structure, encompassing Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions, contributed to this growth, with strong performance noted across several key areas, including molecular diagnostics and bioprocessing. Danaher also reaffirmed its commitment to strategic capital allocation and operational excellence through the Danaher Business System (DBS). Looking ahead, Danaher announced its intention to separate its Environmental & Applied Solutions (EAS) segment into a standalone publicly traded company in the fourth quarter of 2023, a move expected to unlock further value. Despite facing headwinds such as supply chain disruptions and inflation, which were largely mitigated through DBS, the company's strategic focus on innovation, customer service, and attracting top talent positions it well for continued growth and value creation. Investors should note the ongoing management of global operations and adaptation to market dynamics, including the impact of foreign currency fluctuations.
Feb 22, 2023
2021
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2021
Danaher Corporation (DHR) reported a strong financial performance for the fiscal year ended December 30, 2021, driven by significant growth across its key segments, particularly Life Sciences and Diagnostics. The company achieved substantial revenue growth, aided by strategic acquisitions, including the significant acquisition of Aldevron. Danaher's robust financial position is underscored by increased operating profit margins and healthy cash flow from operations, demonstrating effective execution of its Danaher Business System (DBS) and strategic priorities. Despite potential headwinds from supply chain disruptions and global economic uncertainties, Danaher's diversified business model and focus on innovation in science and technology markets have allowed it to navigate these challenges effectively. The company's commitment to attracting and retaining talent, coupled with ongoing investments in research and development, positions it for continued growth and value creation for shareholders. Investors can look forward to Danaher's continued focus on portfolio enhancement through strategic capital allocation and operational excellence.
Feb 23, 2022
2020
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2020
Danaher Corporation (DHR) reported strong performance in its 2020 fiscal year, characterized by significant revenue growth driven primarily by the substantial acquisition of Cytiva and robust core sales growth across its segments. The Life Sciences segment showed particular strength, bolstered by Cytiva's performance and demand related to COVID-19 testing and vaccine development. The company navigated the challenges of the COVID-19 pandemic effectively, demonstrating resilience through its diversified business model and the application of the Danaher Business System (DBS). While the pandemic did impact certain areas of the business, overall, Danaher managed operational and financial impacts, leveraging cost-saving measures and adapting to changing market dynamics. The company's strong operating profit margins and cash flow generation underscore its operational efficiency and financial health, positioning it well for continued growth and strategic investments in science and technology.
Feb 25, 2021
2019
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2019
Danaher Corporation's 2019 10-K filing highlights a year of strategic expansion and operational focus. The company reported a 5.0% increase in consolidated sales to $17.9 billion, driven by a 6.0% core sales growth, indicating strong underlying performance across its Life Sciences, Diagnostics, and Environmental & Applied Solutions segments. A significant event was the pending $21 billion acquisition of GE Biopharma, which was expected to close in Q1 2020 and positioned Danaher for substantial growth in the life sciences sector. The company also completed the disposition of its Dental business (Envista) through an IPO and split-off, generating proceeds that were used to manage its capital structure. Danaher continued to emphasize its Danaher Business System (DBS) for operational improvements and demonstrated a commitment to innovation through research and development investments. The financial outlook appears robust, with increasing sales and operating profit, despite investments related to the large GE Biopharma acquisition and other strategic initiatives. The company managed its debt effectively, even as it incurred additional debt to finance the GE Biopharma acquisition. Danaher's diversified business model across multiple industries and geographies provided resilience against market fluctuations. Investors should note the ongoing integration of acquired businesses and the strategic importance of the GE Biopharma acquisition for future growth and market positioning.
Feb 21, 2020
2018
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2018
Danaher Corporation reported solid performance for the fiscal year ending December 31, 2018, with total sales reaching $19.9 billion, an increase of 8.5% year-over-year. The company's strategic priorities, including portfolio enhancement, the application of the Danaher Business System (DBS), and talent acquisition, continue to drive value. The Life Sciences and Diagnostics segments were key growth drivers, supported by acquisitions such as Integrated DNA Technologies (IDT) in the Life Sciences segment. A significant strategic move announced was the intention to spin off the Dental business into an independent, publicly-traded company in the second half of 2019. This separation is expected to be tax-free to shareholders and aims to allow Danaher to better focus on its core Life Sciences, Diagnostics, and Environmental & Applied Solutions segments. The company also reported strong operating profit margins, reflecting effective cost management and operational improvements.
Feb 21, 2019
2017
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2017
Danaher Corporation's 2017 10-K filing reveals a year of robust sales growth driven by its Life Sciences and Diagnostics segments, which together represented over 60% of total revenue. The company's strategic focus on portfolio enhancement through acquisitions, operational improvements via the Danaher Business System (DBS), and talent management continues to be a core driver of its performance. Despite a challenging macroeconomic environment and increased competition in some markets, Danaher demonstrated resilience with core sales growth, indicating underlying strength in its diverse business units. The company's commitment to innovation and customer-centricity is evident in its continued investment in research and development across all segments. Financially, Danaher reported strong sales growth, supported by strategic acquisitions and organic growth initiatives. The company managed its debt effectively, with a focus on maintaining a healthy balance sheet. Investors should note the impact of the Tax Cuts and Jobs Act of 2017, which introduced significant changes to the U.S. tax landscape, including a one-time Transition Tax. Danaher provided a provisional estimate for its impact, aiming for a future effective tax rate between 20-21%. The company's diversified business model, global reach, and consistent application of DBS provide a solid foundation for continued value creation.
Feb 21, 2018
2016
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2016
Danaher Corporation's 2016 10-K report highlights a year of significant strategic moves and growth, driven by its "Danaher Business System" (DBS) and a focus on enhancing its portfolio in science and technology markets. The company successfully executed the separation of its former Test & Measurement and Industrial Technologies segments into Fortive Corporation, a move that streamlined its operations and allowed for a more concentrated focus on its core segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. Financially, Danaher demonstrated robust sales growth, driven by both existing businesses and strategic acquisitions, notably the significant acquisition of Cepheid. The company also managed its debt effectively, utilizing proceeds from the Fortive separation to repay existing notes. Danaher's commitment to innovation and operational efficiency through DBS appears to be a key driver of its performance, positioning it for continued growth in its specialized markets. The report underscores the company's diversified business model and global reach as strengths in navigating economic uncertainties.
Feb 22, 2017
2015
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2015
Danaher Corporation's 2015 10-K filing reveals a company strategically positioned for significant transformation with a notable increase in debt driven by the substantial acquisition of Pall Corporation. Despite a strong revenue growth of 7.5% to $20.6 billion, operating profit saw a slight decrease to $3.47 billion due to acquisition-related charges, separation costs, and currency headwinds. The company is actively preparing to split into two distinct entities: a science and technology-focused "New Danaher" and a diversified industrial firm named "Fortive." This separation, slated for the third quarter of 2016, is a key strategic move aiming to unlock value and allow each entity to pursue tailored growth strategies. Financially, the period was marked by the large-scale Pall acquisition, significantly increasing total assets and long-term debt. While operating cash flow remained robust, the substantial debt load taken on for the acquisition warrants investor attention. The company maintained its commitment to shareholders through dividends, and its diversified business segments across Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies provided a resilient revenue base. The Life Sciences & Diagnostics segment, bolstered by Pall, became the largest revenue contributor. Investors should monitor the successful integration of Pall and the execution of the forthcoming corporate separation.
Feb 24, 2016
2014
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2014
Danaher Corporation reported robust performance for the fiscal year ending December 31, 2014, demonstrating sales growth driven by both existing businesses and strategic acquisitions. The company's diversified five-segment structure, encompassing Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies, contributed to its stable global performance. Danaher's commitment to its "Danaher Business System" (DBS) continues to be a key driver for operational efficiency and innovation across its diverse product and service offerings. Financially, the company saw an increase in consolidated sales of 4.0% compared to the prior year. Management highlighted a strategic acquisition of Nobel Biocare in the Dental segment, alongside sixteen other acquisitions across various segments, reinforcing its growth-through-acquisition strategy. The company also announced plans to spin off or split off its communications business from the Test & Measurement segment and merge it with NetScout Systems, Inc., a significant strategic move expected to be completed in 2015. Danaher's financial health appears solid, with substantial cash from operations and manageable debt levels.
Feb 25, 2015
2013
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2013
Danaher Corporation's 2013 10-K filing highlights a diversified company with five key segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies. The company's strategy is centered on driving shareholder value through sales growth exceeding market growth, achieving upper-quartile financial performance, and generating strong cash flow, all underpinned by the Danaher Business System (DBS). Financially, the company demonstrated revenue growth driven by both existing businesses and acquisitions, with approximately 58% of sales generated internationally. While facing some market challenges and currency headwinds, Danaher continued to invest in R&D, with expenditures totaling $1.25 billion. The company also actively managed its capital structure, reducing debt and approving a new share repurchase program. Key financial indicators such as sales, operating profit, and net earnings showed an upward trend compared to the previous year, reflecting the company's operational execution and strategic acquisitions.
Feb 21, 2014
2012
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2012
Danaher Corporation's 2012 10-K filing reveals a company focused on diversified growth through its five key segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies. The company emphasizes its Danaher Business System (DBS) as a core driver for continuous improvement in quality, delivery, cost, and innovation. Strategic acquisitions played a significant role in expanding its portfolio, notably the substantial acquisition of Beckman Coulter in 2011, which bolstered the Life Sciences & Diagnostics segment. The company also actively manages its portfolio through divestitures of non-core assets. The report highlights consistent sales growth, driven by both organic improvements and strategic acquisitions, with a notable presence in high-growth markets. Danaher demonstrates a commitment to shareholder value through consistent dividend payments and a share repurchase program, alongside a robust approach to managing its financial resources and operational efficiencies.
Feb 22, 2013
2011
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2011
Danaher Corporation reported robust growth in its 2011 fiscal year, driven by strong performance across its diverse segments, particularly the Life Sciences & Diagnostics division, which was significantly bolstered by the acquisition of Beckman Coulter. The company's strategic focus on the Danaher Business System (DBS) continues to be a key driver of operational efficiency and value creation. Danaher maintained a strong financial position, evidenced by healthy operating cash flow and a diverse revenue stream across its five reportable segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies. The company's acquisition strategy remains active, with continued investment in businesses that align with its strategic goals and enhance its market positions, alongside the divestiture of non-core assets. Looking ahead, Danaher anticipates continued sales growth from existing businesses, albeit at a moderating pace, supported by ongoing investments in innovation and market expansion, particularly in emerging markets. The integration of Beckman Coulter is expected to yield significant synergies and contribute to future growth. The company's financial health is supported by a well-managed debt structure and ample liquidity, positioning it to pursue strategic opportunities while navigating the evolving economic landscape.
Feb 24, 2012
2010
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2010
Danaher Corporation (DHR) reported a strong financial performance for the fiscal year ending December 31, 2010, marking a significant recovery from the economic downturn of 2009. The company experienced substantial sales growth, driven by increased demand across its diverse segments and successful integration of recent acquisitions, particularly in the Life Sciences & Diagnostics sector. Danaher's focus on operational efficiency, through its Danaher Business System (DBS), continued to yield positive results, leading to improved operating profit margins. The company strategically deployed capital through acquisitions, enhancing its market positions and technological capabilities. Looking ahead, Danaher anticipates continued sales growth, albeit at a moderating pace, and remains committed to its strategy of organic growth supplemented by targeted acquisitions. The company's financial health is robust, supported by strong operating cash flow and a well-managed balance sheet. Investors can find confidence in Danaher's diversified business model, its disciplined capital allocation, and its consistent execution of its strategic initiatives, positioning it for sustained shareholder value creation.
Feb 24, 2011
2009
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2009
Danaher Corporation's 2010 10-K filing for the fiscal year ending December 31, 2009, reveals a company navigating the challenging economic conditions of 2009. Despite a significant 12% year-over-year sales decline, Danaher demonstrated resilience by maintaining operating profit margins through cost-saving measures and restructuring actions. The company actively pursued growth through strategic acquisitions, completing 15 businesses during the year, and significantly expanding its presence in life sciences and diagnostics with key acquisitions post-year-end. Financially, Danaher managed its liquidity effectively, generating substantial operating cash flow and reducing inventory levels. The company also took steps to strengthen its financial position by issuing new debt. While facing headwinds from reduced customer demand and currency fluctuations, Danaher's diversified business segments and ongoing commitment to the Danaher Business System provided a foundation for anticipated modest sales growth in 2010 and a focus on continued operational improvements and strategic investments.
Feb 24, 2010
2008
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2008
Danaher Corporation's 2008 Form 10-K filing reveals a company navigating a challenging economic environment, marked by a significant increase in sales driven by acquisitions, particularly the large Tektronix acquisition in late 2007. Despite overall revenue growth, the company experienced a notable slowdown in demand in the fourth quarter of 2008 due to the deteriorating global economic conditions. Management responded with restructuring actions to align costs with the prevailing economic climate, expecting significant savings in 2009. The company's diversified business segments—Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools & Components—demonstrated varying resilience, with environmental and acute care diagnostic businesses showing strength, while industrial and consumer-oriented segments faced greater headwinds. Danaher's strategic focus on the Danaher Business System (DBS) for continuous improvement, coupled with an aggressive acquisition strategy, remains central to its value creation approach. Investors should monitor the integration of acquired businesses and the company's ability to adapt to ongoing economic uncertainty.
Feb 25, 2009
2007
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2007
Danaher Corporation's 2007 10-K filing reveals a year of significant growth, driven by strategic acquisitions and expansion across its four key segments: Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools & Components. The company reported a substantial increase in sales, bolstered by the integration of newly acquired businesses, most notably Tektronix, Inc. and ChemTreat, Inc. These acquisitions are expected to contribute to future growth and operational efficiencies. Danaher continues to leverage its Danaher Business System (DBS) to drive performance improvements in quality, delivery, cost, and innovation across its diverse portfolio. Financially, the company demonstrated robust operating cash flow generation. Despite significant investment in acquisitions, Danaher maintained a strong liquidity position. The company also continued its share repurchase program and paid dividends, reflecting a commitment to shareholder returns. Management highlighted ongoing efforts to improve operating profit margins through cost reduction initiatives and strategic sourcing. The company's global reach, with over half of its sales generated outside the U.S., provides diversification and resilience against regional economic fluctuations.
Feb 21, 2008
2006
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2006
Danaher Corporation reported strong performance for the fiscal year ended December 31, 2006, driven by significant sales growth and strategic acquisitions, particularly in the Medical Technologies segment. The company's revenue increased by 20% year-over-year, with acquisitions contributing approximately 13% of this growth. Danaher's diversified business model, spanning Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools & Components, helped mitigate the impact of any single industry downturn. The company's commitment to its Danaher Business System (DBS) continues to be a key driver for operational improvements and cost efficiencies across its segments. Financially, Danaher demonstrated robust operating cash flow generation, which was utilized to fund substantial acquisition activity totaling approximately $2.7 billion in 2006. The company also managed its debt effectively, partly by issuing commercial paper and Eurobond notes. Danaher's focus on delivering shareholder value through growth, financial performance, and cash flow generation remains central to its strategy, supported by ongoing investments in new products and market expansion, particularly in emerging markets.
Mar 1, 2007
2005
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2005
Danaher Corporation's 2005 10-K filing reveals a year of significant growth driven by strategic acquisitions, particularly in the Medical Technologies segment. The company reported a 16% increase in sales, with acquisitions contributing approximately 11.5% of this growth. Professional Instrumentation emerged as the largest segment, fueled by expansion in environmental, electronic test, and medical technologies. Despite overall positive performance, the company navigated increasing raw material costs and a moderating growth rate compared to the prior year. Danaher's commitment to its Danaher Business System (DBS) remains central to its strategy for continuous improvement in quality, delivery, cost, and innovation, aiming for upper quartile financial performance and cash flow generation. The company also continued its share repurchase program and maintained a strong liquidity position with substantial cash reserves and available credit facilities.
Mar 15, 2006
2004
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2004
Danaher Corporation's 2004 10-K filing reveals a year of significant growth, primarily driven by strategic acquisitions that expanded its presence in the Medical Technology sector and strengthened its existing segments. The company reported substantial revenue increases, demonstrating effective integration of new businesses and continued organic growth in its core Professional Instrumentation, Industrial Technologies, and Tools & Components segments. Danaher's commitment to its business system (DBS) appears to be a key driver for operational improvements and competitive positioning. Financially, the company generated strong operating cash flow, which was largely utilized for its aggressive acquisition strategy. While managing increased debt levels, Danaher maintained a solid liquidity position. Investors can note the company's continued focus on shareholder value through growth and performance, coupled with a proactive approach to managing operational efficiencies and potential market risks.
Mar 7, 2005
2003
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2003
Danaher Corporation's 2003 10-K report highlights a year of significant growth, driven by both organic improvements and strategic acquisitions. The company's Process/Environmental Controls segment, which represents the majority of its revenue (77%), saw strong performance bolstered by its Environmental, Motion, Electronic Test, and Product Identification platforms. The Tools & Components segment also contributed, albeit with a smaller share (23%). Financially, Danaher demonstrated robust operating cash flow generation, increasing by approximately 21% over the prior year, and maintained a strong liquidity position with substantial cash reserves. The company actively pursued its growth strategy through acquisitions, investing significantly in businesses that complement its existing operations or establish new strategic platforms, particularly in the burgeoning medical technology sector. Looking ahead, Danaher expressed confidence in its ability to integrate these acquisitions and anticipates continued revenue growth, supported by its proprietary Danaher Business System (DBS) aimed at continuous performance improvement.
Mar 10, 2004
2002
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 2002
Danaher Corporation's 2002 10-K filing highlights a year of significant strategic acquisitions, particularly within the Process/Environmental Controls segment, which now represents 74% of the company's revenue. The Tools & Components segment experienced modest growth. The company demonstrated strong operational cash flow generation and free cash flow growth, reflecting disciplined capital allocation and effective execution of its Danaher Business System principles. Despite facing market softness in certain sectors, such as semiconductor and electronic assembly, and increased geopolitical uncertainties impacting some end markets, Danaher's diversified business model and strategic acquisitions provided resilience and growth. The company also addressed a significant accounting change with the adoption of SFAS No. 142, leading to the cessation of goodwill amortization and an associated impairment charge. Management remains focused on both organic growth initiatives and continued pursuit of strategic acquisitions to drive future expansion and market share gains. The filing also details robust liquidity, a manageable debt structure, and provides insights into the company's operational segments and risk management strategies.
Mar 28, 2003
2001-A
DANAHER CORP /DE/ Annual Report (Amendment), Year Ended Dec 31, 2001
This filing is an amendment to Danaher Corporation's 2001 Form 10-K, providing supplemental information related to related-party transactions. Key disclosures involve arrangements with Colfax Corporation, a company where the Rales brothers are controlling stockholders, regarding the distribution of "wrap spring clutch" products. Danaher sold approximately $3.1 million of these products to Colfax in 2001, under terms consistent with other distributors, and has since entered into a new three-year distribution agreement. Additionally, the report details cost-sharing agreements for leased aircraft operations and office space with Equity Group Holdings LLC and its affiliates, which Danaher believes result in cost efficiencies. These arrangements, while involving related parties, appear to be conducted on an arm's-length basis and are presented as beneficial to Danaher.
Aug 14, 2002
1998
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 1998
Danaher Corporation's 1998 Form 10-K shows a company that grew sharply through acquisitions. Sales rose about 17% to $2.91 billion, and the Pacific Scientific acquisition ($420 million) and Dr. Lange GmbH drove much of the increase, with the Fluke Corporation merger accounted for as a pooling of interests. Operating profit rose 22% to $366.8 million, and gross margin improved 1.5 points to 37.4%. Diluted EPS was $1.32, which includes a $0.21 after-tax charge from the Fluke merger. Excluding that charge, earnings would have been higher. Process/Environmental Controls (55.5% of sales) grew fastest, with a 24% sales increase and operating margin rising to 13.8%, while Tools and Components grew 8.5% with a 12.3% operating margin. The balance sheet took on more leverage. Total debt rose from $199 million to $473 million, largely to fund $526 million of net acquisition payments, and total assets grew to $2.74 billion. Operating cash flow of $331 million covered $90 million of capital expenditures, and the company had $250 million of unused revolver capacity at year-end. Management describes the funding position as sufficient for the foreseeable future. Equity rose to $1.35 billion, and retained earnings grew to $979 million. Key risks include customer concentration (Sears, Roebuck accounted for about 10% of 1998 sales), indemnification exposure from a former subsidiary's air tool product liability litigation (maximum obligation of about $85 million, with a settlement agreed in principle), environmental liabilities from JMC's former wood-treating operations, and integration risk from recent acquisitions. The filing also notes that the Year 2000 and Euro conversion costs were not material. Note that the selected financial data table contains some apparent typographical errors, such as a 1996 operating profit shown as 67,406 instead of 267,406 in the income statement.
Mar 19, 1999
1997
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 1997
Danaher Corporation's 1997 annual report shows a company growing revenue and earnings through both acquisitions and organic demand. Sales rose 13% to $2.05 billion from $1.81 billion, and operating profit increased 18% to $266.9 million. Net earnings fell to $154.8 million, or $2.57 diluted EPS, from $207.8 million in 1996. That decline is a comparison issue, not a deterioration: 1996 included an approximately $80 million one-time gain from the sale of Fayette Tubular Products. Earnings from continuing operations grew 21% to $154.8 million, and diluted EPS from continuing operations rose 21% from $2.13 to $2.57. The business is split between Tools and Components (58% of 1997 sales, with 12.1% operating margins) and Process/Environmental Controls (42% of sales, with 16.0% margins, driven by Veeder-Root leak detection and acquisitions). Gross margin expanded 1.0 point to 32.6%, and operating cash flow reached $278 million, comfortably funding $63 million of capital expenditures, $147 million of acquisitions, and $38 million of debt reduction. Total debt fell to $198 million and the company has $250 million of unused revolving credit capacity. Key risks include customer concentration (Sears accounted for 13% of sales), a long-tail product liability indemnification tied to a former subsidiary (up to roughly $85 million, with about 3,000 plaintiffs), and environmental exposure from JMC's former wood-treating operations. Management also flagged the March 1998 acquisition of Pacific Scientific, which will be consolidated from Q1 1998 and is expected to be a major expansion of the company's electric motor and safety equipment businesses.
Mar 17, 1998
1996-A
DANAHER CORP /DE/ Annual Report (Amendment), Year Ended Dec 31, 1996
Danaher Corporation's 1996 Form 10-K shows a company that grew revenue sharply through acquisitions while improving profitability. Net revenues rose 22% to $1.81 billion (from $1.49 billion), and operating profit grew 25% to $226.1 million. Net earnings more than doubled to $207.8 million ($3.47 per share), but this figure includes an approximately $80 million one-time gain from the January 1996 sale of Fayette Tubular Products. Earnings from continuing operations rose 21% to $128.0 million ($2.13 per share). Gross margin improved 1.5 points to 31.6%, while SG&A rose to 19.1% of sales, reflecting the higher cost structure of acquired businesses. The company operates two segments. Tools and Components (60.9% of revenue, 11.6% operating margin) is anchored by its Sears Craftsman and NAPA relationships. Sears alone accounted for about 14% of 1996 sales, which the company acknowledges could adversely affect operations if lost. Process/Environmental Controls (39.1% of revenue) grew 47% on the Joslyn and Acme-Cleveland acquisitions and is positioned around underground storage tank leak detection (Veeder-Root), a business tied to environmental regulation. Its operating profit rose 39%, though segment margins are lower than the prior year's level after the Joslyn and Hengstler deals. Balance-sheet and cash-flow trends are solid. Operating cash flow reached $217 million, debt fell $48 million to $236 million, and stockholders' equity rose to $800 million. Acquisitions consumed $246 million in cash. Risk factors include a product liability indemnification exposure of up to about $85 million tied to a former air tool subsidiary, a class action involving the former Joslyn wood-treating operations, and environmental remediation obligations. Management states it believes these are not expected to have a material adverse effect, though the outcome of some matters cannot yet be predicted.
Apr 28, 1997
1996
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 1996
Danaher Corporation's 1996 10-K shows a company in rapid expansion through acquisition. Net revenues rose 22% to $1.81 billion from $1.49 billion, and operating profit grew 25% to $226.1 million. Net earnings more than doubled to $207.8 million ($3.47 per share), but this figure is inflated by an approximately $80 million after-tax gain on the January 1996 sale of Fayette Tubular Products, a discontinued operation. Earnings from continuing operations rose 21% to $128.0 million ($2.13 per share), which is the more reliable measure of underlying performance. Growth was driven largely by the July 1996 Acme-Cleveland acquisition (about $200 million) and the full-year effect of the September 1995 Joslyn acquisition (about $245 million). Gross margin improved 1.5 points to 31.6%, while SG&A rose to 19.1% of sales, reflecting the higher cost structure of acquired businesses. The company operates two segments. Tools and Components (61% of revenue) includes Sears Craftsman tools, Matco, and Jacobs Chuck, with a 11.6% operating margin. Process/Environmental Controls (39% of revenue) is the faster-growing segment, up 47%, with a 15.8% margin, and is anchored by Veeder-Root underground fuel-tank leak detection products. Balance sheet leverage remains modest: total debt fell to $236 million from $284 million, and operating cash flow reached $217 million. Key risks include customer concentration, with Sears accounting for 14% of sales, a pending product liability suit involving air tools with up to $85 million of indemnification exposure, and environmental and wood-treating litigation at former Joslyn sites.
Mar 28, 1997
1995-A2
DANAHER CORP /DE/ Annual Report (Amendment), Year Ended Dec 31, 1995
Danaher Corporation's 1995 Annual Report shows a company in strong growth mode, driven primarily by acquisitions. Net revenues rose 33% to $1.487 billion in 1995 from $1.114 billion in 1994, while operating profit increased 45% to $180.3 million. Earnings before the cumulative effect of accounting change reached $108.3 million, or $1.81 per share, up from $1.40 per share in 1994, a 29% increase. Net earnings were $108.3 million, with continuing operations and discontinued operations (Fayette Tubular Products) both contributing. Growth was concentrated in two segments. Tools and Components revenue grew 24% to $1.005 billion, with operating profit up 39%, reflecting manufacturing process improvements and the Joslyn acquisition. Process/Environmental Controls revenue grew 58% to $482 million, with acquisitions (notably Hengstler and Joslyn) contributing 52 points of the increase, though segment operating margin fell from 18.6% to 16.8% due to those deals. Gross margin improved 1.2 points to 30.1%, and the effective tax rate fell to 38.9%. The balance sheet took on more leverage to fund roughly $245 million for Joslyn and other acquisitions. Operations generated $174 million in cash, against $59 million of capital expenditures and $231 million of acquisition spending, and debt rose $98 million. Management states that internal cash flow, its $250 million unused revolver and available credit lines should cover working capital, capex, dividends and debt service for the foreseeable future. The Fayette sale for $155 million closed in January 1996, with an expected gain of about $80 million in the first quarter of 1996.
Oct 8, 1996
1995-A
DANAHER CORP /DE/ Annual Report (Amendment), Year Ended Dec 31, 1995
Danaher Corporation's 1995 annual results show strong growth driven by acquisitions and operating leverage. Net revenues rose 33% to $1.49 billion from $1.11 billion, and operating profit rose 45% to $180.3 million, lifting the operating margin from 11.2% to 12.1%. Net earnings increased 33% to $108.3 million, or $1.81 per share, from $81.7 million, or $1.40 per share. Gross margin improved to about 30.1% from 28.9%. Much of the growth came from the September 1995 Joslyn Corporation acquisition (about $245 million) and 1994 acquisitions. Operating cash flow grew to $174.2 million, but capital spending nearly doubled to $59.2 million, and total debt increased to $283.6 million from $185.3 million. The balance sheet and portfolio changes matter for investors. Long-term debt rose to $268.6 million, and the company agreed in December 1995 to sell Fayette Tubular Products for about $155 million. Management expects a pre-tax gain of about $80 million in the first quarter of 1996, and the proceeds were earmarked to repay substantially all remaining short-term debt. Fayette is now reported as discontinued operations. The Tools and Components segment remains the largest business at $1.0 billion in revenue, with a 16% customer concentration, while Process/Environmental Controls grew to $482 million in revenue with a higher 16.8% operating margin. The main risk factors are environmental and litigation exposures. Environmental compliance accruals jumped to $88.2 million from $11.6 million, largely due to the Joslyn wood-treating sites, and the company states that estimates may change. Product liability claims tied to former air tool operations involve about 3,000 plaintiffs, with a maximum indemnification obligation of about $85 million that the company believes is substantially insured. Management states that pending legal matters are not expected to have a materially adverse effect on financial condition, but a class action tied to Joslyn's Louisiana site cannot yet be quantified.
Sep 13, 1996
1995
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 1995
Danaher Corporation's 10-K for fiscal 1995 shows a company in rapid expansion through acquisition. Net revenues rose 33% to $1.487 billion (from $1.114 billion), and earnings from continuing operations rose 46% to $105.8 million, or $1.77 per share. Growth was driven mainly by the September 1995 acquisition of Joslyn Corporation for roughly $245 million, along with 1994 acquisitions including Delta Consolidated, Hengstler and Armstrong Brothers. Gross margin improved to 30.1% from 28.9%, and operating profit climbed to $180.3 million from $124.4 million. The balance sheet took on more leverage. Long-term debt more than doubled to $268.6 million, and total debt, including current portions and notes payable, rose to about $283.6 million. Environmental compliance accruals jumped to $88.2 million from $11.6 million, largely tied to Joslyn's legacy wood-treating operations. Management says operating cash flow of $174 million comfortably covers capital expenditures, dividends and debt service. Shareholders' equity grew to $586 million. Risk concentration and legal exposure remain notable. Sears, Roebuck accounted for about 16% of 1995 sales, and management warns that losing this business could materially harm operations. The company also faces product-liability indemnification claims from a former air-tool subsidiary (about 3,000 plaintiffs, with a maximum indemnity of roughly $85 million) and a Louisiana class action tied to JMC. Post-year-end, the sale of Fayette Tubular Products for $155 million is expected to produce a gain of roughly $80 million in Q1 1996, which will likely boost reported earnings.
Mar 21, 1996
1994-A
DANAHER CORP /DE/ Annual Report (Amendment), Year Ended Dec 31, 1994
This is an amended annual report (Form 10-K/A) for Danaher Corporation for the fiscal year ended December 31, 1994. The amendment adds only Exhibit 27, the Financial Data Schedules, so the filing contains no income statement, balance sheet, cash flow, segment, or management discussion data. The text provided is the cover page and exhibit index. Financial performance cannot be assessed from this document alone. The full 10-K and the Annual Report to Securityholders (Exhibit 13), which the index references, would be needed for that analysis. The cover page provides basic profile data. Danaher is a Delaware corporation headquartered in Washington, D.C., with common stock listed on the New York and Pacific Stock Exchanges. As of March 20, 1995, 58,438,288 common shares were outstanding, held by approximately 2,800 holders of record. The aggregate market value of shares held by non-affiliates was approximately $900 million. That figure implies a rough per-share value of about $15 for non-affiliate shares, though this is an approximation based on the total non-affiliate float and not a reported price. The exhibit index points to several material agreements that bear on the company's capital structure and operations: a 1990 credit agreement with Bankers Trust Company as agent, 1992 and 1993 note agreements with institutional lenders, a 1990 agreement between Danaher, Easco Hand Tools, Inc., and Sears, Roebuck and Co., and an employment agreement with CEO George M. Sherman. Most of these are incorporated by reference to earlier filings rather than reproduced here.
Apr 27, 1995
1994
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 1994
Danaher Corporation's fiscal 1994 10-K shows a company with strong top-line growth and substantially improved profitability. Net revenues rose 19.8% to $1.29 billion from $1.08 billion, and operating profit increased 44% to $145.8 million, lifting the operating margin to 11.3% from 9.4%. Gross margin expanded 1.3 points to 27.5%, and SG&A fell to 16.2% of sales, which management attributes to productivity gains, cost reductions, and volume leverage. Earnings before the 1993 accounting change grew 52% to $81.7 million. Reported 1994 EPS of $1.40 reflects the January 1995 two-for-one stock split, and the comparison with 1993's $0.31 is distorted by a $36 million non-cash charge for post-retirement benefit accounting (SFAS 106) in 1993. Growth came from all three segments and was driven largely by volume. Tools (45% of sales) grew 16%, Process/Environmental Controls grew 24% on strong demand for underground storage tank leak detection systems, and Transportation grew 23% on a cyclical rebound in automotive and heavy-truck markets. Growth was also supported by acquisitions totaling about $167 million, including Delta Consolidated Industries, Hengstler GmbH, and Armstrong Brothers Tool. Hengstler closed on December 30, 1994, so its results are not in 1994 figures, and the other acquisitions contributed little to 1994 results because most closed in the fourth quarter. The balance sheet and cash flow remain manageable but show higher leverage. Total assets grew to $1.13 billion and total debt rose to $185 million, while equity increased to $476 million. Operating cash flow of $144 million covered $55 million of capital expenditures, though acquisitions required net new borrowing. Key risks for investors include customer concentration (Sears accounted for 17% of sales), cyclicality in the Transportation segment, and a product liability indemnification tied to a former subsidiary's air tools, with about 3,000 plaintiffs and maximum exposure of roughly $85 million that management believes is substantially insured.
Mar 23, 1995
1993
DANAHER CORP /DE/ Annual Report, Year Ended Dec 31, 1993
Danaher Corporation (DHR) filed this Form 10-K (annual report) with the SEC on March 23, 1994, covering the period ended December 31, 1993. The copy of this filing on the SEC's EDGAR system contains only the submission header, with no document text, so there is nothing to summarize. The record confirms that the filing was made and when. For Danaher Corporation's results and disclosures from this period, see its other filings from around March 1994.
Mar 23, 1994